ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $83.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target boosted by Raymond James from $81.00 to $83.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Raymond James’ target price would suggest a potential upside of 37.46% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. Truist Financial reiterated a “hold” rating and set a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $60.38 on Wednesday. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The firm has a market cap of $1.27 billion, a P/E ratio of 37.74 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average of $61.14 and a 200-day moving average of $63.76.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period last year, the company earned $1.06 EPS. Sell-side analysts expect that ANI Pharmaceuticals will post 3.5 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,007 shares of company stock valued at $2,911,790. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. Innealta Capital LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $85,000. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals during the first quarter valued at $106,000. ADAR1 Capital Management LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter worth about $132,000. Finally, Clear Street Markets LLC purchased a new position in ANI Pharmaceuticals in the 4th quarter worth about $140,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.